LIGHTFIELD STUDIOS/AdobeStock
CONFERENCE REPORTER
In a current research, investigators in contrast charges of somnolence/sedation with dopamine partial agonists vs D2 receptor antagonists within the adjunctive therapy of main depressive dysfunction (MDD) and the therapy of acute schizophrenia. Knowledge had been introduced on the 2025 American Society of Medical Psychopharmacology Annual Assembly in Scottsdale, AZ.1
Somnolence/sedation are each opposed results related to the usage of some atypical antipsychotics within the therapy of MDD and schizophrenia. They disrupt sleep high quality, can intrude with each day functioning, and negatively impression total high quality of life.2-5 The chance of somnolence/sedation can play a big position in influencing affected person and supplier selections relating to atypical antipsychotic therapy.6-8
Atypical antipsychotics might be categorized as both dopamine partial agonists, which act as practical agonists or antagonists relying on the encompassing ranges of endogenous dopamine, or dopamine D2 receptor antagonists (eg, quetiapine), which act as pure antagonists at these receptors.9 Nonetheless, the relative charges of somnolence/sedation related to dopamine partial agonists vs D2 receptor antagonists in MDD or schizophrenia are unclear. Investigators sought to higher perceive these charges by conducting 2 impartial meta-analyses that used research recognized by prior systematic literature evaluations.
The adjunctive MDD meta-analysis included randomized, double-blind, placebo-controlled, part 2 and three trials with a randomization part ≥6 weeks evaluating atypical antipsychotics accredited by the US Meals and Drug Administration for the adjunctive therapy of MDD in adults. The trials that had been included assessed somnolence as a binary end result.
The schizophrenia meta-analysis included double-blind, randomized, managed trials with a randomization part ≥4 weeks evaluating atypical antipsychotics for the therapy of acute schizophrenia in adults. The trials that had been included trials assessed somnolence/sedation as a binary end result. Excluded from the evaluation had been research populations with first episode schizophrenia, predominant unfavourable signs, or refractory illness. In research that reported each somnolence and sedation, the end result with the best variety of occasions was reported.
Investigators then used Bayesian community meta-analyses (NMAs) to guage the therapy impact of dopamine partial agonists and D2 receptor antagonists on somnolence in MDD or somnolence/sedation in schizophrenia. Statistical assessments of heterogeneity had been primarily based on mannequin match comparisons between fixed- and random-effects fashions utilizing the deviance info criterion (DIC). For schizophrenia, which used a random-effects mannequin, one other statistical measure (Ƭ2) was calculated.
For MDD, investigators included 10 research, then used a fixed-effects mannequin for evaluation, as a result of a decrease DIC in contrast with the random-effects mannequin (40.4 vs 41.8, respectively). The chances of experiencing somnolence had been 72% much less for sufferers taking dopamine partial agonists in contrast with these taking D2 receptor antagonists (OR [95% CrI], 0.28 [0.13, 0.59]).
For schizophrenia, investigators included 50 research. The chances of experiencing somnolence/sedation had been 57% much less for sufferers taking dopamine partial agonists in contrast with these taking D2 receptor antagonists (OR [95% CrI], 0.43 [0.26, 0.73]).
There was low to average heterogeneity noticed for the random-effects mannequin on somnolence/sedation (Ƭ2=0.14), which means that the variability amongst research outcomes is comparatively low. Investigators concluded that dopamine partial agonists could also be much less prone to trigger somnolence in MDD or somnolence/sedation in schizophrenia in contrast with D2 receptor antagonists.
References
1. Nabulsi N, Ta J, Haile F, et al. Oblique therapy comparability of somnolence or sedation with dopamine partial agonists versus D2 receptor antagonists in main depressive dysfunction and schizophrenia. Poster introduced at: 2025 American Society of Medical Psychopharmacology Annual Assembly; Could 27-30, 2025; Scottsdale, AZ. Accessed Could 29, 2025.
2. Valencia Carlo YE, Saracco-Alvarez RA, Carlo VAV, et al. Adversarial results of antipsychotics on sleep in sufferers with schizophrenia. Systematic evaluate and meta-analysis. Entrance Psychiatry. 2023;14:1189768.
3. Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic therapy for main depressive dysfunction: a meta-analysis of despair, high quality of life, and security outcomes. Focus (Am Psychiatr Publ). 2016;14(2):244-265.
4. Hofstetter JR, Lysaker PH, Mayeda AR. High quality of sleep in sufferers with schizophrenia is related to high quality of life and coping. BMC Psychiatry. 2005;5:13.
5. Takaesu Y, Kanda Y, Nagahama Y, et al. Delayed sleep-wake rhythm is related to cognitive dysfunction, social dysfunction, and deteriorated high quality of life in sufferers with main depressive dysfunction. Entrance Psychiatry. 2022;13:1022144.
6. Ng-Mak D, Poon JL, Roberts L, et al. Affected person preferences for essential attributes of bipolar despair therapies: a discrete alternative experiment. Affected person Choose Adherence. 2018;12:35-44.
7. Jorgensen TR, Emborg C, Dahlen Okay, et al. Affected person preferences for drugs administration for acute agitation: outcomes from an internet-based survey of sufferers recognized with bipolar dysfunction or schizophrenia in two Nordic nations. Psychol Well being Med. 2018;23(1):30-38.
8. Doane MJ, Boeri M, Vass C, et al. Preferences for attributes of oral antipsychotic therapies: outcomes from a discrete-choice experiment in respondents with schizophrenia or bipolar I dysfunction. BMC Psychiatry. 2024;24(1):605.
9. Lieberman JA. Dopamine partial agonists: a brand new class of antipsychotic. CNS Medication. 2004;18(4):251-267.
